Journal
RSC ADVANCES
Volume 5, Issue 99, Pages 81668-81681Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c5ra16757d
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81201182]
- Natural Science Foundation of Jiangsu Province [BK20150702]
- Fundamental Research Funds for the Central Universities [JKPZ2013006]
- Ministry of Education of China [20130096120003]
Ask authors/readers for more resources
A hyaluronic acid-platinum(IV) nanoconjugate with a high drug loading capacity was developed to mitigate the side effects of platinum(II). Pt(IV), HA-EDA, and HA-EDA-Pt(IV) nanoconjugates were investigated by H-1 NMR, C-13 NMR, FT-NIR, and DSC. Negatively charged polymer-drug conjugates were of a uniform size around 186.4 nm and spherical in shape. In vitro antiproliferation and in vivo apoptosis assays proved that the nanomedicine possessed high cytotoxicity towards cancer cells. The enhanced antitumor effect was attributed to HA receptor-mediated endocytosis. Nanoscale conjugates exhibited desirable blood compatibility and negligible stimulation to blood vessels. The systemic toxicity study showed that polymer-drug conjugates were much safer than the parent drug evidenced by biochemical and histological analyses. The concise design of the nanoconjugate offers a simple way to overcome the toxicity and non-selectivity of cisplatin, which could improve therapeutical outcomes of platinum drugs in cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available